FDA explains the ins and outs of real-time oncology review program in new guidance

Regulatory NewsRegulatory NewsBiologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyResearch, Design and Development